Jonathan Soll

Associate

2024 - Current

New Rhein applies a private equity business model to life sciences venture capital investing. Our goal is to develop products that deliver compelling health benefits to patients and compelling economic value to payers.

Analyst

2022 - 2023

Analyst

2018 - 2022

Analyst for an event-driven investment firm. Deeply involved in idea-generation, due diligence and execution of multiple strategies. Developed a deep understanding of complicated health insurance industry rules, regulations and decisions and how they affected the value of publicly traded medical device companies. The resulting trading strategy resulted in substantial profits for the firm. Additionally, managed and traded a yield arbitrage portfolio that drove consistent income with a high Sharpe ratio. Supported the team with data analytics and software development, developed proprietary software in Python used to monitor and alert the team on material events that affect the valuation of public companies. Performed extensive due diligence of public company valuation via financial analysis and discounted cash flow (DCF) modeling.

Senior Data Analyst

2018 - 2018

Created a suite of metrics, KPIs, analytics, reports and dashboards to improve HR department functions, driving material improvement in the company’s recruiting process, recruiter efficiency, candidate experience, and talent acquisition management performance evaluation. Used big data analytics to to develop a lead-generation strategy to identify motivated customers in the mortgage market. Worked directly with C-level executives, performing deep-dive analysis of company data to deliver data-driven recommendations on topics including employee compensation, HR practices, and revenue forecasting.

Data Analyst

2016 - 2018

Associate

2016 - 2016

Community Manager

2015 - 2016

Summer Equity Research Associate

2015 - 2015

Fund Manager

2014 - 2015

Marketing Manager

2014 - 2015

Database Manager

2014 - 2014